Abbvie Inc. Common Stock (ABBV) 64.52 $ABBV
Forget Google: 5 Top Stocks With Earnings Thursday
at Investor's Business Daily - 54 mins ago
Tech titan Google (GOOGL) will make headlines with its quarterly earnings after the close on Thursday. But Google's growth is sluggish and the stock is lackluster. Check out these five stocks with better performance than the search giant, including...
AMZN: 389.80 (-1.38), PCYC: 256.98 (-0.77), MO: 52.12 (+0.02), ALK: 64.31 (-0.62), LUV: 42.85 (-0.18), SBUX: 48.33 (-0.04), GILD: 104.18 (-1.02), ALXN: 188.19 (+1.41), GM: 37.16 (unch), GOOGL: 549.18 (+6.26), ABBV: 64.52 (+0.91), PG: 83.09 (+0.01), MSFT: 42.98 (+0.35), DOW: 50.02 (+0.37)
Notable earnings before Thursday’s open
Seeking Alpha - at Seeking Alpha - 2 hrs 54 mins ago
CAM: 49.02 (+0.36), BBT: 38.87 (+0.21), LAZ: 56.56 (-0.08), JAH: 51.68 (-0.16), ASPS: 18.07 (+1.32), HSY: 98.33 (+0.31), CAB: 53.76 (-0.12), CFX: 48.68 (+0.12), FAF: 36.74 (+0.57), HP: 73.53 (+1.48), KKR: 23.37 (+0.21), AEP: 56.14 (+0.17), DNKN: 47.72 (+0.21), CLFD: 15.63 (+0.19), DAN: 21.57 (+0.18), ABBV: 64.52 (+0.91), CSL: 94.86 (+0.78), CAT: 84.87 (+0.95), BHE: 24.51 (-0.19), AVT: 45.49 (+0.28), IR: 67.49 (+0.29), COR: 48.82 (-0.57), ALK: 64.31 (-0.62), COL: 96.55 (+0.45), BKU: 33.64 (+0.12), BCC: 38.42 (-0.13), MJN: 98.92 (-1.00), IQNT: 18.03 (+0.28), ERIC: 12.70 (-0.09), DGX: 76.29 (+0.08), ALXN: 188.19 (+1.41), DOW: 50.02 (+0.37), DST: 116.35 (+0.44), MDP: 52.99 (-0.41), MMM: 164.67 (+0.67), GRA: 97.10 (+0.03), FCX: 20.57 (+0.34), CLI: 18.28 (-0.01), DHR: 85.25 (+0.05), FNB: 13.21 (+0.10), LUV: 42.85 (-0.18), DPS: 78.81 (-0.38), IVC: 19.80 (+0.24), GMT: 59.92 (+0.42), JNS: 17.93 (unch), DPZ: 99.80 (+0.40), DLX: 69.57 (+0.47), CMS: 35.07 (+0.15), LTM: 71.60 (+0.17), MDSO: 47.66 (+0.43), LLY: 72.30 (+0.09), BMS: 44.00 (+0.09), EQT: 87.29 (+0.85), MHO: 23.74 (-0.25), BTU: 4.87 (+0.06), GPK: 14.24 (+0.15), BAX: 70.38 (+0.33), EQM: 83.89 (+0.08), BEAV: 63.43 (-0.01), GM: 37.16 (unch), HUB.B: 110.19 (-0.19), JCI: 51.33 (+0.30)
Gilead hopes to drive international demand for hep C drugs by giving some away
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 1:01PM CDT
GILD: 104.18 (-1.02), ABBV: 64.52 (+0.91)
Biotech Stock Roundup: Amgen Starts Earnings Season on Strong Note, Setbacks for Ampio & Athersys - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 22, 12:21PM CDT
Amgen's (AMGN) first quarter 2015 results were impressive and the company raised its earnings outlook for the year.
BIIB: 423.57 (+1.46), ALNY: 118.00 (-2.70), GILD: 104.18 (-1.02), MDCO: 27.84 (+0.25), AMGN: 169.10 (+0.64), AMPE: 2.89 (+0.20), ABBV: 64.52 (+0.91), ATHX: 1.34 (+0.01)
AbbVie reports tomorrow
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 11:30AM CDT
ABBV: 64.52 (+0.91)
St. Jude, Abbott Labs Beat Q1 Expectations
at Investor's Business Daily - Wed Apr 22, 9:54AM CDT
Two medical-product giants were rising in the stock market early Wednesday after beating first-quarter expectations. St. Jude Medical (STJ) jumped 6.5% to a new high above 73 after it reported earnings of 91 cents a share, up 6% from the year-earlier...
ABT: 48.35 (+1.23), STJ: 73.55 (+4.43), ABBV: 64.52 (+0.91)
Gilead Sciences Vs. AbbVie: Which Is A Better Buy?
Mycroft - at Seeking Alpha - Wed Apr 22, 7:49AM CDT
JNJ: 100.43 (+0.13), ABT: 48.35 (+1.23), PCYC: 256.98 (-0.77), GILD: 104.18 (-1.02), SHPG: 253.58 (+3.70), ABBV: 64.52 (+0.91)
Pharmacyclics Announces Positive Results on Imbruvica - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 4:54PM CDT
Pharmacyclics (PCYC) announced positive long-term follow-up data on Imbruvica.
BIIB: 423.57 (+1.46), JNJ: 100.43 (+0.13), PCYC: 256.98 (-0.77), ABBV: 64.52 (+0.91)
Will Alexion's (ALXN) Soliris Drive Q1 Earnings Beat? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 4:10PM CDT
Alexion Pharmaceuticals, Inc. is scheduled to report first-quarter 2015 earnings results on Apr 23 before the opening bell.
BIIB: 423.57 (+1.46), IMGN: 9.96 (+0.01), ALXN: 188.19 (+1.41), ABBV: 64.52 (+0.91)
Pharma Spends Big On M&A In Q1 As Teva Pulls Trigger On Mylan
EP Vantage - Seeking Alpha - Tue Apr 21, 2:25PM CDT
The pharma and biotech buying spree showed no sign of abating in the opening months of 2015, with $69bn committed across 62 deals in the first quarter, EvaluatePharma data show. And with Teva (NYSE: TEVA ) confirming its interest in ...
AGN: 240.22 (+2.88), VRX: 206.93 (-3.92), ACT: 295.22 (+0.69), PFE: 34.93 (+0.04), MYL: 72.40 (-1.67), ABBV: 64.52 (+0.91), TEVA: 63.01 (-1.15)
Is AbbVie (ABBV) Set to Top 1Q Earnings on Humira & HCV? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 2:14PM CDT
Will AbbVie (ABBV) surpass earnings expectations in 1Q on the back of strong Humira and Viekira sales?
BIIB: 423.57 (+1.46), PCYC: 256.98 (-0.77), IMGN: 9.96 (+0.01), ABBV: 64.52 (+0.91)
5 Reasons To Consider Gilead
David Sims - at Seeking Alpha - Tue Apr 21, 1:02PM CDT
GILD: 104.18 (-1.02), ABBV: 64.52 (+0.91)
Forget Gilead (GILD), Buy These Impressive Biotech Stocks Instead - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 8:09AM CDT
It's time we overlooked Gilead for some biotech growth stocks.
BIIB: 423.57 (+1.46), JNJ: 100.43 (+0.13), ESRX: 86.12 (+0.02), PCYC: 256.98 (-0.77), GILD: 104.18 (-1.02), ANTH: 4.79 (+0.10), GERN: 4.20 (-0.04), ABBV: 64.52 (+0.91)
World CNS Therapeutics Industry
PR Newswire - Mon Apr 20, 2:07PM CDT
This report analyzes the worldwide markets for CNS Therapeutics in US$ Million by the following Product Groups: Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 145 companies including many key and niche players such as -
ABBV: 64.52 (+0.91)
Will Abbott Labs (ABT) Disappoint on Earnings This Quarter? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 20, 12:29PM CDT
Abbott Labs' track record was impressive in 2014 with the company beating estimates comfortably in all the four quarters.
BIIB: 423.57 (+1.46), ABT: 48.35 (+1.23), AMGN: 169.10 (+0.64), ABBV: 64.52 (+0.91)
AbbVie extends exchange offer to purchase Pharmacyclics to 1 May 2015
M2 - Mon Apr 20, 8:23AM CDT
Biopharmaceutical company AbbVie (NYSE:ABBV)( SIX:ABBV) revealed on Friday the extension of the expiration of its exchange offer to acquire all of the outstanding shares of common stock of Pharmacyclics to 17:00 p.m., New York City time, on 1 May 2015.
ABBV: 64.52 (+0.91)
Double-Digit Spike in Drug Costs Prescribes Profits for PBMs
Bruce Japsen, The Motley Fool - Motley Fool - Mon Apr 20, 8:21AM CDT
The spike in employer spending on prescription drugs is now forecast to jump around 10% for the next three years, according to a new report that puts pressure on companies to dramatically alter pharmacy benefits. And while that's bad news for...
ESRX: 86.12 (+0.02), CTRX: 59.46 (-0.11), GILD: 104.18 (-1.02), UNH: 117.81 (-1.47), CVS: 101.23 (-0.18), AON: 97.20 (+0.10), ABBV: 64.52 (+0.91)
Human Papillomavirus and Cytomegalovirus Therapeutics Market - Global Industry Analysis 2015 for the $2.34 Billion Market
M2 - Mon Apr 20, 8:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8lwwcf/_human) has announced the addition of the "Human Papillomavirus (By Drug Class and Applications) and Cytomegalovirus (By Drug Type and Applications) Therapeutics Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. The global HPV therapeutics market was valued at USD 1,402.3 million in 2012 and is expected to reach USD 2,346.5 million by 2020, growing at a CAGR of 7.7% from 2014 to 2020. Human papillomavirus (HPV) and Cytomegalovirus (CMV) therapeutics market report studies current as well as future prospects of the market on a global scale. The global market for HPV therapeutics is segmented by drug class and applications. Various drug classes applied against HPV infections are immunomodulators, keratolytic agents, anti-neoplastic agents, and sinecatechins. The HPV therapeutics market is studied by application segments which include genital warts, genital cancers, epidermodysplasia verriformis, oral papillomas, and others (oropharyngeal cancer, laryngeal papillomatosis and others). The global HPV therapeutics market has been extensively analyzed on the basis of the effectiveness and sales revenue of major drug classes as well as geographic prevalence of various HPV infections. The global CMV therapeutics market is segmented by drugs and applications. The major drugs prescribed for the treatment of CMV infections are ganciclovir, valganciclovir, foscarnet, and cidofovir. The CMV therapeutics treatment is applied against various CMV infections causing retinitis, pneumonia, gastrointestinal ulcers, encephalitis and others (mouth ulcers, pharyngitis and others). Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Global HPV and CMV Therapeutics Market Overview Chapter 4 Global HPV Therapeutics Market Chapter 5 Global Cytomegalovirus Therapeutics Market Chapter 6 Global HPV and CMV Therapeutics Market, by Geography Chapter 7 Recommendations Chapter 8 Company Profiles - AbbVie, Inc. - Actavis plc - Clinigen Group plc - Merck & Co., Inc. - Perrigo Company plc - Roche Holdings AG - Valeant Pharmaceuticals International, Inc. For more information visit http://www.researchandmarkets.com/research/8lwwcf/_human
PRGO: 201.50 (+8.68), MRK: 57.69 (+0.03), ABBV: 64.52 (+0.91), VRX.TO: 253.14 (-6.24)
What Could Possibly Go Wrong With Gilead Sciences Inc. Stock?
Keith Speights, The Motley Fool - Motley Fool - Sat Apr 18, 9:02AM CDT
Source: Wikimedia Commons . Chip and Dan Heath give valuable advice on making decisions in their book "Decisive: How to Make Better Choices in Life and Work". In the book, the Heath brothers recommend taking four actions to make better decisions:...
ESRX: 86.12 (+0.02), GILD: 104.18 (-1.02), MRK: 57.69 (+0.03), ABBV: 64.52 (+0.91)
AbbVie Extends Exchange Offer to Acquire Pharmacyclics, Inc.
PR Newswire - Fri Apr 17, 3:47PM CDT
AbbVie Inc. ("AbbVie"
(NYSE / CHX / Euronext Paris / SIX: ABBV) today announced that it has extended the expiration of its exchange offer to acquire all of the outstanding shares of common stock of Pharmacyclics, Inc. to 5 p.m., New York City time, on May 1, 2015.
PCYC: 256.98 (-0.77), ABBV: 64.52 (+0.91)
Forget Google: 5 Top Stocks With Earnings Thursday
at Investor's Business Daily - 54 mins ago
Tech titan Google (GOOGL) will make headlines with its quarterly earnings after the close on Thursday. But Google's growth is sluggish and the stock is lackluster. Check out these five stocks with better performance than the search giant, including...
AMZN: 389.80 (-1.38), PCYC: 256.98 (-0.77), MO: 52.12 (+0.02), ALK: 64.31 (-0.62), LUV: 42.85 (-0.18), SBUX: 48.33 (-0.04), GILD: 104.18 (-1.02), ALXN: 188.19 (+1.41), GM: 37.16 (unch), GOOGL: 549.18 (+6.26), ABBV: 64.52 (+0.91), PG: 83.09 (+0.01), MSFT: 42.98 (+0.35), DOW: 50.02 (+0.37)
Notable earnings before Thursday’s open
Seeking Alpha - at Seeking Alpha - 2 hrs 54 mins ago
CAM: 49.02 (+0.36), BBT: 38.87 (+0.21), LAZ: 56.56 (-0.08), JAH: 51.68 (-0.16), ASPS: 18.07 (+1.32), HSY: 98.33 (+0.31), CAB: 53.76 (-0.12), CFX: 48.68 (+0.12), FAF: 36.74 (+0.57), HP: 73.53 (+1.48), KKR: 23.37 (+0.21), AEP: 56.14 (+0.17), DNKN: 47.72 (+0.21), CLFD: 15.63 (+0.19), DAN: 21.57 (+0.18), ABBV: 64.52 (+0.91), CSL: 94.86 (+0.78), CAT: 84.87 (+0.95), BHE: 24.51 (-0.19), AVT: 45.49 (+0.28), IR: 67.49 (+0.29), COR: 48.82 (-0.57), ALK: 64.31 (-0.62), COL: 96.55 (+0.45), BKU: 33.64 (+0.12), BCC: 38.42 (-0.13), MJN: 98.92 (-1.00), IQNT: 18.03 (+0.28), ERIC: 12.70 (-0.09), DGX: 76.29 (+0.08), ALXN: 188.19 (+1.41), DOW: 50.02 (+0.37), DST: 116.35 (+0.44), MDP: 52.99 (-0.41), MMM: 164.67 (+0.67), GRA: 97.10 (+0.03), FCX: 20.57 (+0.34), CLI: 18.28 (-0.01), DHR: 85.25 (+0.05), FNB: 13.21 (+0.10), LUV: 42.85 (-0.18), DPS: 78.81 (-0.38), IVC: 19.80 (+0.24), GMT: 59.92 (+0.42), JNS: 17.93 (unch), DPZ: 99.80 (+0.40), DLX: 69.57 (+0.47), CMS: 35.07 (+0.15), LTM: 71.60 (+0.17), MDSO: 47.66 (+0.43), LLY: 72.30 (+0.09), BMS: 44.00 (+0.09), EQT: 87.29 (+0.85), MHO: 23.74 (-0.25), BTU: 4.87 (+0.06), GPK: 14.24 (+0.15), BAX: 70.38 (+0.33), EQM: 83.89 (+0.08), BEAV: 63.43 (-0.01), GM: 37.16 (unch), HUB.B: 110.19 (-0.19), JCI: 51.33 (+0.30)
Gilead hopes to drive international demand for hep C drugs by giving some away
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 1:01PM CDT
GILD: 104.18 (-1.02), ABBV: 64.52 (+0.91)
Biotech Stock Roundup: Amgen Starts Earnings Season on Strong Note, Setbacks for Ampio & Athersys - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 22, 12:21PM CDT
Amgen's (AMGN) first quarter 2015 results were impressive and the company raised its earnings outlook for the year.
BIIB: 423.57 (+1.46), ALNY: 118.00 (-2.70), GILD: 104.18 (-1.02), MDCO: 27.84 (+0.25), AMGN: 169.10 (+0.64), AMPE: 2.89 (+0.20), ABBV: 64.52 (+0.91), ATHX: 1.34 (+0.01)
AbbVie reports tomorrow
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 11:30AM CDT
ABBV: 64.52 (+0.91)
St. Jude, Abbott Labs Beat Q1 Expectations
at Investor's Business Daily - Wed Apr 22, 9:54AM CDT
Two medical-product giants were rising in the stock market early Wednesday after beating first-quarter expectations. St. Jude Medical (STJ) jumped 6.5% to a new high above 73 after it reported earnings of 91 cents a share, up 6% from the year-earlier...
ABT: 48.35 (+1.23), STJ: 73.55 (+4.43), ABBV: 64.52 (+0.91)
Gilead Sciences Vs. AbbVie: Which Is A Better Buy?
Mycroft - at Seeking Alpha - Wed Apr 22, 7:49AM CDT
JNJ: 100.43 (+0.13), ABT: 48.35 (+1.23), PCYC: 256.98 (-0.77), GILD: 104.18 (-1.02), SHPG: 253.58 (+3.70), ABBV: 64.52 (+0.91)
Pharmacyclics Announces Positive Results on Imbruvica - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 4:54PM CDT
Pharmacyclics (PCYC) announced positive long-term follow-up data on Imbruvica.
BIIB: 423.57 (+1.46), JNJ: 100.43 (+0.13), PCYC: 256.98 (-0.77), ABBV: 64.52 (+0.91)
Will Alexion's (ALXN) Soliris Drive Q1 Earnings Beat? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 4:10PM CDT
Alexion Pharmaceuticals, Inc. is scheduled to report first-quarter 2015 earnings results on Apr 23 before the opening bell.
BIIB: 423.57 (+1.46), IMGN: 9.96 (+0.01), ALXN: 188.19 (+1.41), ABBV: 64.52 (+0.91)
Pharma Spends Big On M&A In Q1 As Teva Pulls Trigger On Mylan
EP Vantage - Seeking Alpha - Tue Apr 21, 2:25PM CDT
The pharma and biotech buying spree showed no sign of abating in the opening months of 2015, with $69bn committed across 62 deals in the first quarter, EvaluatePharma data show. And with Teva (NYSE: TEVA ) confirming its interest in ...
AGN: 240.22 (+2.88), VRX: 206.93 (-3.92), ACT: 295.22 (+0.69), PFE: 34.93 (+0.04), MYL: 72.40 (-1.67), ABBV: 64.52 (+0.91), TEVA: 63.01 (-1.15)
Is AbbVie (ABBV) Set to Top 1Q Earnings on Humira & HCV? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 2:14PM CDT
Will AbbVie (ABBV) surpass earnings expectations in 1Q on the back of strong Humira and Viekira sales?
BIIB: 423.57 (+1.46), PCYC: 256.98 (-0.77), IMGN: 9.96 (+0.01), ABBV: 64.52 (+0.91)
5 Reasons To Consider Gilead
David Sims - at Seeking Alpha - Tue Apr 21, 1:02PM CDT
GILD: 104.18 (-1.02), ABBV: 64.52 (+0.91)
Forget Gilead (GILD), Buy These Impressive Biotech Stocks Instead - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 21, 8:09AM CDT
It's time we overlooked Gilead for some biotech growth stocks.
BIIB: 423.57 (+1.46), JNJ: 100.43 (+0.13), ESRX: 86.12 (+0.02), PCYC: 256.98 (-0.77), GILD: 104.18 (-1.02), ANTH: 4.79 (+0.10), GERN: 4.20 (-0.04), ABBV: 64.52 (+0.91)
World CNS Therapeutics Industry
PR Newswire - Mon Apr 20, 2:07PM CDT
This report analyzes the worldwide markets for CNS Therapeutics in US$ Million by the following Product Groups: Anti-Alzheimer's, Anti-Parkinson's, Anti-Epilepsy, Pain Management, Anti-Psychotics, Anti-Depressants, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 145 companies including many key and niche players such as -
ABBV: 64.52 (+0.91)
Will Abbott Labs (ABT) Disappoint on Earnings This Quarter? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 20, 12:29PM CDT
Abbott Labs' track record was impressive in 2014 with the company beating estimates comfortably in all the four quarters.
BIIB: 423.57 (+1.46), ABT: 48.35 (+1.23), AMGN: 169.10 (+0.64), ABBV: 64.52 (+0.91)
AbbVie extends exchange offer to purchase Pharmacyclics to 1 May 2015
M2 - Mon Apr 20, 8:23AM CDT
Biopharmaceutical company AbbVie (NYSE:ABBV)( SIX:ABBV) revealed on Friday the extension of the expiration of its exchange offer to acquire all of the outstanding shares of common stock of Pharmacyclics to 17:00 p.m., New York City time, on 1 May 2015.
ABBV: 64.52 (+0.91)
Double-Digit Spike in Drug Costs Prescribes Profits for PBMs
Bruce Japsen, The Motley Fool - Motley Fool - Mon Apr 20, 8:21AM CDT
The spike in employer spending on prescription drugs is now forecast to jump around 10% for the next three years, according to a new report that puts pressure on companies to dramatically alter pharmacy benefits. And while that's bad news for...
ESRX: 86.12 (+0.02), CTRX: 59.46 (-0.11), GILD: 104.18 (-1.02), UNH: 117.81 (-1.47), CVS: 101.23 (-0.18), AON: 97.20 (+0.10), ABBV: 64.52 (+0.91)
Human Papillomavirus and Cytomegalovirus Therapeutics Market - Global Industry Analysis 2015 for the $2.34 Billion Market
M2 - Mon Apr 20, 8:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8lwwcf/_human) has announced the addition of the "Human Papillomavirus (By Drug Class and Applications) and Cytomegalovirus (By Drug Type and Applications) Therapeutics Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020" report to their offering. The global HPV therapeutics market was valued at USD 1,402.3 million in 2012 and is expected to reach USD 2,346.5 million by 2020, growing at a CAGR of 7.7% from 2014 to 2020. Human papillomavirus (HPV) and Cytomegalovirus (CMV) therapeutics market report studies current as well as future prospects of the market on a global scale. The global market for HPV therapeutics is segmented by drug class and applications. Various drug classes applied against HPV infections are immunomodulators, keratolytic agents, anti-neoplastic agents, and sinecatechins. The HPV therapeutics market is studied by application segments which include genital warts, genital cancers, epidermodysplasia verriformis, oral papillomas, and others (oropharyngeal cancer, laryngeal papillomatosis and others). The global HPV therapeutics market has been extensively analyzed on the basis of the effectiveness and sales revenue of major drug classes as well as geographic prevalence of various HPV infections. The global CMV therapeutics market is segmented by drugs and applications. The major drugs prescribed for the treatment of CMV infections are ganciclovir, valganciclovir, foscarnet, and cidofovir. The CMV therapeutics treatment is applied against various CMV infections causing retinitis, pneumonia, gastrointestinal ulcers, encephalitis and others (mouth ulcers, pharyngitis and others). Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Global HPV and CMV Therapeutics Market Overview Chapter 4 Global HPV Therapeutics Market Chapter 5 Global Cytomegalovirus Therapeutics Market Chapter 6 Global HPV and CMV Therapeutics Market, by Geography Chapter 7 Recommendations Chapter 8 Company Profiles - AbbVie, Inc. - Actavis plc - Clinigen Group plc - Merck & Co., Inc. - Perrigo Company plc - Roche Holdings AG - Valeant Pharmaceuticals International, Inc. For more information visit http://www.researchandmarkets.com/research/8lwwcf/_human
PRGO: 201.50 (+8.68), MRK: 57.69 (+0.03), ABBV: 64.52 (+0.91), VRX.TO: 253.14 (-6.24)
What Could Possibly Go Wrong With Gilead Sciences Inc. Stock?
Keith Speights, The Motley Fool - Motley Fool - Sat Apr 18, 9:02AM CDT
Source: Wikimedia Commons . Chip and Dan Heath give valuable advice on making decisions in their book "Decisive: How to Make Better Choices in Life and Work". In the book, the Heath brothers recommend taking four actions to make better decisions:...
ESRX: 86.12 (+0.02), GILD: 104.18 (-1.02), MRK: 57.69 (+0.03), ABBV: 64.52 (+0.91)
AbbVie Extends Exchange Offer to Acquire Pharmacyclics, Inc.
PR Newswire - Fri Apr 17, 3:47PM CDT
AbbVie Inc. ("AbbVie"
(NYSE / CHX / Euronext Paris / SIX: ABBV) today announced that it has extended the expiration of its exchange offer to acquire all of the outstanding shares of common stock of Pharmacyclics, Inc. to 5 p.m., New York City time, on May 1, 2015. PCYC: 256.98 (-0.77), ABBV: 64.52 (+0.91)
